Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised…

Overview of attention for article published in The Lancet, April 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

blogs: 1 blog
policy: 2 policy sources
twitter: 7 X users
patent: 6 patents

facebook: 1 Facebook page
wikipedia: 4 Wikipedia pages
guideline: 2 clinical guideline sources

Readers on

mendeley: 177 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 28,569 followers.

New Ultralong-Acting Basal #Insulin Lowers Risk for Overnight #Hypoglycemia http://t.co/svfBKYCi

Insulin degludec versus glargine in basal-bolus treatment - http://t.co/zNe1gD5F

RT @rincondesisifo: (Lancet) Insulina degludec en DM1 http://t.co/iyMa8Rwm y DM2 http://t.co/sWFubGPI ECA

(Lancet) Insulina degludec en DM1 http://t.co/iyMa8Rwm y DM2 http://t.co/sWFubGPI ECA

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.